
Paediatric chronic kidney disease (CKD) is a progressive and life-altering condition that is associated with substantial comorbidities, reduced life expectancy and considerable burdens on children, families and health care systems. Despite advances in supportive medical management, therapeutic development in paediatric CKD remains sparse. Breakthroughs in the treatment of adult CKD have further exposed the therapeutic and regulatory challenges in paediatric care, underscoring an urgent need for coordinated innovation across the discovery-to-translation continuum. In this Roadmap, which was developed through an international, multidisciplinary collaboration involving paediatric and adult nephrologists, paediatric pharmacologists, biostatisticians, experts in regulatory science and health technology assessment, industry representatives and patient advocates, we articulate the therapeutic needs of children with CKD, summarize the current landscape and delineate critical constraints in clinical trial design. We also highlight the need for surrogate end-point qualification, innovative and adaptive trial methodologies, and coordinated global efforts to accelerate therapeutic innovation and address unmet needs in this underserved population. In this Roadmap, the authors outline the therapeutic needs of children with chronic kidney disease, summarize the current landscape and delineate critical constraints in clinical-trial design. They also highlight potential approaches to overcoming these challenges and accelerating therapeutic innovation for paediatric chronic kidney disease.
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers (TCEs) have potential as effective desensitization therapies in highly sensitized kidney transplant candidates. Clinical utility will depend on balancing treatment-related risks against the potential survival and quality-of-life benefits of facilitated transplantation.
Diabetic kidney disease (DKD) is a leading cause of kidney failure and excess morbidity and mortality. Once regarded as a uniform microvascular complication of chronic hyperglycaemia, DKD is now recognized as a biologically and clinically heterogeneous condition. Not all chronic kidney disease in individuals with diabetes can be attributed to diabetes, and distinguishing DKD from non-diabetic kidney disease (non-DKD) is essential for appropriate management. Multiple interacting pathways, including hyperglycaemia, haemodynamic stress, dyslipidaemia, obesity, inflammation and ancestry-specific genetic risk, drive diverse patterns of kidney injury and clinical trajectories. Conventional classification based on glomerular filtration rate or albuminuria alone fails to capture this complexity. Emerging multi-omics approaches are reshaping our understanding of DKD by identifying genomic, epigenomic, proteomic and metabolomic signatures that stratify risk, elucidate mechanisms and inform therapeutic response. Integration of these molecular layers with polygenic scores, data-driven clustering and single-cell kidney atlases is beginning to define disease endotypes and guide precision-medicine strategies. Large-scale collaborative efforts that combine deep phenotyping, biobanking and advanced analytics are accelerating the translation of molecular heterogeneity into actionable biomarkers and therapeutic targets. Despite ongoing challenges — including the need for validation, equitable representation and clinical implementation — omics-driven precision approaches offer the potential to transform DKD management by reducing residual risk and enabling more effective, precision interventions. This Review discusses the heterogeneity of diabetic kidney disease, focusing on biologically defined subtypes and their underlying mechanisms. The authors highlight emerging molecular pathways and therapeutic targets and discuss how these insights can inform approaches to improve prevention, detection and treatment of diabetic kidney disease.
Innovation in kidney replacement is entering a transformative era. Although precision medicine has driven major breakthroughs in disease-specific therapies, progress in translating next-generation kidney replacement strategies into practice has lagged. This updated Roadmap highlights a shift toward bold, integrative approaches that merge engineering, biology and patient-centred design. Emerging directions include reimagining filtration and tubular function through biomimetic membranes, cellular systems and organ-on-chip technologies, and simultaneously exploring microbiome modulation and sorbent-based strategies to reduce the uraemic toxin burden. Beyond improving survival, new solutions are being shaped by priorities of mobility, sustainability and quality of life, pointing toward wearable and implantable systems that move care beyond the clinic. Biologic frontiers such as xenotransplantation and stem cell regeneration are opening pathways to potentially curative therapies, although challenges in safety, equity and scalability remain. Central to these efforts is the need to embed patient perspectives and ensure that innovations align with lived experiences. This integrative approach calls for renewed investment, regulatory clarity and cross-sector collaboration to accelerate translation of advances into equitable therapies redefining the future of kidney health. New insights into glomerular filtration barrier function, tubular sensing and electrolyte transport, and advances in the development of artificial kidney and synthetic molecular transport systems have created new opportunities for kidney function replacement systems. This Roadmap explores opportunities and challenges in developing innovative kidney replacement therapies, highlighting the importance of integrating global and patient perspectives into innovation strategies.
Human serum albumin, the most abundant protein in human plasma, exerts a multitude of physiological functions that extend beyond its canonical roles in oncotic pressure and solute transport. It acts as a dynamic interface in redox regulation, toxin clearance, immune modulation and pharmacokinetics. In chronic kidney disease, dialysis and transplantation, albumin has diagnostic and therapeutic relevance far surpassing that of a nutritional marker. Emerging insights into the structure–function relationships of albumin, including its binding dynamics, redox isoforms and post-translational modifications, challenge the current paradigm of albumin in chronic kidney disease, which focuses on preserving quantity, and suggest that a shift towards restoring quality might have clinical benefits. Here, we propose two new conceptual frameworks, the ‘albumin paradox’, which reconsiders albumin removal during dialysis as a potentially therapeutic mechanism, and the ‘inflammation-mitigation hypothesis’, which positions albumin functionality as a target in extracorporeal immune modulation. Integrating biophysical, pathophysiological and clinical perspectives, we aim to reframe albumin from a merely passive bystander and laboratory parameter to a modifiable determinant of systemic health and disease. Albumin has roles in toxin transport, antioxidant defence and inflammatory regulation that extend beyond its use as a nutritional marker. Here, the authors discuss changes in albumin abundance and quality across chronic kidney disease and kidney failure, and consider the potential therapeutic benefits of controlled albumin removal during dialysis.